Daewoong Pharmaceutical surged more than 7% during trading on the 3rd, drawing strong interest from investors. Securities firms' projections that second-quarter earnings will significantly exceed market expectations, driven by expanded exports of the botulinum toxin 'Nabota' to the United States, fueled the stock's rally.

As of the morning of that day, Daewoong Pharmaceutical was trading at 133,500 won, up 9,000 won (over 7%) from the previous trading day. While the domestic stock market has recently shown a trend of differentiation among individual stocks, the influx of buying is analyzed to be driven by expectations for export growth and profitability improvement.

**DB Financial Investment: "Q2 Operating Profit of 71.1 Billion Won... Significantly Exceeds Market Consensus"

In a report released that day, DB Financial Investment projected Daewoong Pharmaceutical's consolidated Q2 revenue to reach 413.9 billion won, a 13.7% year-on-year increase. Operating profit was forecast at 71.1 billion won, also growing 13.7%, resulting in an operating profit margin (OPM) of 17.2%. In particular, the estimated operating profit surpassed the market consensus of 51.2 billion won by nearly 20 billion won.

**Nabota Export Expansion Drives Earnings Improvement... Medium- to Long-Term Growth Expectations Also Rise

Securities firms analyzed that steadily expanding Nabota exports in the U.S. market are leading earnings improvement. Nabota, Daewoong Pharmaceutical's core global product, serves as the central axis of its overseas market strategy, and increased global sales, including in the U.S., are evaluated as positively impacting both revenue growth and profitability enhancement.

The market views future overseas sales expansion and improved product competitiveness as key variables that will determine the earnings growth trend. Projections suggest that if rising brand awareness and diversification of export countries continue, the foundation for medium- to long-term growth will become even more solid.

Investors are focusing on the upcoming Q2 earnings release, along with sales trends in overseas markets and the potential expansion of major pharmaceutical exports. Securities firms also anticipate that if U.S.-centered growth continues, the earnings improvement trend will become even more pronounced this year.

[This article was written with the assistance of AI. This article is not an investment recommendation, and investment decisions and their associated responsibilities lie solely with the investor.]